Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 3.5Cr |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.06% | +7.20% | +54.04% | +111.13% | 7.43TCr | |
| -2.29% | -1.51% | +33.30% | +75.15% | 6.12TCr | |
| +0.28% | +7.27% | +31.74% | +23.80% | 2.75TCr | |
| -1.34% | -3.16% | -18.35% | +360.47% | 2.64TCr | |
| -1.88% | +3.24% | +0.68% | -4.06% | 2.53TCr | |
| +0.57% | +3.66% | +25.59% | -9.08% | 2.08TCr | |
| -1.47% | +4.46% | -8.09% | +513.33% | 1.49TCr | |
| +1.29% | -2.49% | +163.31% | +333.06% | 1.52TCr | |
| -2.40% | +0.04% | +42.69% | +160.22% | 1.44TCr | |
| Average | -0.80% | +3.20% | +36.10% | +173.78% | 3.11TCr | |
| Weighted average by Cap. | -0.85% | +3.08% | +35.58% | +134.80% |
